BioPharmSignal logoBioPharmSignal

Biotech News

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

Lineage Cell Therapeutics (LCTX)Lineage Cell TherapeuticsCompany update

CARLSBAD, Calif. --(BUSINESS WIRE)--Jul. 6, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that Brian M.

Related news

LCTXLineage Cell Therapeutics2026-08-06 20:01 EST

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

LCTXLineage Cell Therapeutics2026-07-30 12:00 EST

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

LENZLenz Therapeutics Inc2026-04-20 12:00 EST

LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom

OCSOculis2026-06-08 19:25 EST

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference

SGHTSight Sciences2026-03-30 20:05 EST

Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th

BLTEBelite Bio2026-04-27 12:00 EST

Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit

OTLKOutlook2026-08-06 12:45 EST

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

OTLKOutlook2026-07-24 18:40 EST

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

OCSOculis2026-06-11 08:00 EST

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

BLTEBelite Bio2026-06-02 12:00 EST

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

View all latest news

Lineage Cell Therapeutics

Pluripotent Cell Therapy Company Lineage Cell Therapeutics develops allogeneic, off-the-shelf cell replacements using its AlloSCOPE pluripotent stem-cell engineering and manufacturing platform. OpRegen RG6501, formerly OpRegen, is a retinal pigment epithelium cell replacement therapy partnered with Roche and Genentech for geographic...

Recent company news

LCTXLineage Cell Therapeutics2026-08-06 20:01 EST

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

LCTXLineage Cell Therapeutics2026-07-30 12:00 EST

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

LCTXLineage Cell Therapeutics2026-07-13 12:00 EST

Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

LCTXLineage Cell Therapeutics2026-07-06 12:00 EST

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

LCTXLineage Cell Therapeutics2026-05-12 20:01 EST

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Stock data

Close
1.13 USD
Market cap
301.65M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States